Recombinant Human GLA Protein ，His

GLA, or galactosylceramidase, is an essential enzyme involved in the metabolism of complex lipids, specifically sphingolipids. Deficiencies in GLA lead to a rare lysosomal storage disorder known as Krabbe disease, which is characterized by severe neurological impairment and early mortality. The need for effective therapeutic interventions has spurred extensive research into the recombinant production of GLA, which can potentially provide a viable treatment option through enzyme replacement therapy (ERT). Advances in recombinant DNA technology have facilitated the expression of human GLA in various systems, enabling the generation of biologically active enzyme for clinical application. Moreover, understanding the structure and function of GLA at the molecular level has been crucial for developing strategies to enhance its stability and efficacy. Additionally, studies focusing on the localization and delivery methods of GLA within the body aim to optimize its therapeutic potential. The ongoing exploration of GLA reconstitution not only holds promise for patients with Krabbe disease but also paves the way for novel approaches in treating other lysosomal storage disorders. As research progresses, the insights gained from GLA studies could lead to advancements in gene therapy and personalized medicine, offering hope for better management of these debilitating conditions.